Riskpilot← Back to searchSign inGet full accessISR Immune System Regulation AB
ABBankruptOrg 5567368690Research and experimental development on natural sciences and engineering · NACE 7210Est. 20070 employees
Revenue 2022
SEK 0
EBITDA margin
—
-45% vs 2021
Equity ratio
-1212.8%
Financial strength
Net profit 2022
SEK -91,6M
-45% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -91,6M | -45% |
| Net profit | SEK -91,6M | -45% |
| Total assets | SEK 4,9M | -83% |
| Equity | SEK -59,1M | -577% |
| Employees | 0 | — |
Legal name
ISR Immune System Regulation AB
Org number
5567368690
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 augusti 2007
Share capital
SEK 148 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet skall bestå i att utveckla immunstimulerande läkemedel inom indikationsområden som infektionssjukdomar inklusive HIV eller AIDS samt även andra aktuella indikationsområden. Även utveckling av immunblockerade läkemedel skall ingå i verksamheten med effekt inom indikationsområden som transplantationer och andra immunologiska sjukdomar där blockering av immunsystemet kan vara aktuell. Denna utveckling skall kommersialiseras samt skall bolaget även starta och förvalta nya bolag inom dessa områden.
Address
Email
johan@jpnylund.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 7 592 | 5 895 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −7 823 | −9 357 | −8 839 | −63 072 | −91 551 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −7 823 | −9 357 | −8 839 | −63 072 | −91 551 |
| Net financials | −126 | −128 | −6 | −1 | −4 |
| Profit before tax | −7 949 | −9 485 | −8 845 | −63 074 | −91 555 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −7 949 | −9 485 | −8 845 | −63 074 | −91 555 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 2 470 | 2 274 | 3 862 | 28 106 | 4 877 |
| Equity | 343 | 868 | 1 481 | 12 407 | −59 148 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 127 | 1 406 | 2 381 | 15 698 | 64 024 |
| Total debt | 2 127 | 1 406 | 2 381 | 15 698 | 64 024 |
EBITDA margin
-9155100000.0%
This company
15.8%
Market median
-57943670986% vs market
20182022
Equity ratio
-1212.8%
This company
38.2%
Market median
-3275% vs market
20182022
Return on equity
-9155500000.0%
This company
18.4%
Market median
-49758152274% vs market
20182022
Net profit margin
-9155500000.0%
This company
8.1%
Market median
-113030864298% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Audit | 2024 | |
SO Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
BM Chief Auditor | Chief Auditor | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Chairman | 2024 | |
| Former (3) | ||
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ISR Immune System Regulation Holding AB (publ)
ISR Immune System Regulation AB Board members of ISR Immune System Regulation AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Magnus Lagerberg | Chief Auditor | 0 companies |
| Ben Behnam Mahajerzadeh-Heidari | Audit | 0 companies |
| Stig Ola Winqvist | Chief Executive Officer | 0 companies |
| Carl Henrik Egertun | Board of Directors | 0 companies |
| Stig Jonas Winqvist | Deputy Board Member | 0 companies |
| Aleksandar Gocic | Board of Directors | 0 companies |
| Johan Peter Nylund | Board of Directors | 0 companies |
| Jan Krister Magnelöv | Chairman | 0 companies |
| Jan Erik Gunnar Jardelöv | Board of Directors | 0 companies |
| Anders Harald Milton | Chairman | 0 companies |